Full Press Release Details
ADVISORY, July 11, 2013 (GLOBE NEWSWIRE) --
MiMedx Group, Inc. [MDXG], an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Mr. Parker H. "Pete" Petit, Chairman & CEO will ring the Opening Bell.
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio
Friday, July 12, 2013 - 9:15 a.m. to 9:30 a.m. ET
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About MiMedx Group, Inc. [MDXG]:
MiMedx is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix and CollaFix , and our tissue technologies, AmnioFix and EpiFix . Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx is the leading supplier of amniotic tissue, having supplied over 160,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
About NASDAQ OMX Group: